-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
This article is from NEJM Journal Watch Does Ondansetron Have a Role in Primary Care Management of Pediatric Gastroenteritis? Can ondansetron play a role in the primary treatment of gastroenteritis in children? Comment by Marie Claire O'Dwyer, MB BCh BAO, MPH Children suffering from gastroenteritis took a single dose of ondansetron and reduced their vomiting
.
Acute gastroenteritis is usually self-limiting, and oral rehydration is the main treatment
.
However, persistent vomiting in the child indicates failure of oral rehydration
.
Emergency department studies have demonstrated the effects of oral ondansetron in restricting vomiting and improving oral rehydration (NEJM JW Gen Med May 15 2006 and N Engl J Med 2006; 354:1698), but its role in primary treatment has not been Clear
.
The trial included 194 children (age range, age range, 6 months to 6 years old), the investigator randomly assigned them to receive standard treatment (only the prescription of oral rehydration solution) or standard treatment combined with a single oral dose of ondansetron (0.
1 mg/kg)
.
The parents of the child will record the child’s symptoms/fluid intake in detail every day for the next 4 hours and the following 7 days
.
Significantly fewer children in the ondansetron group had vomiting in the next 4 hours (19.
5% vs.
42.
9%), and parents in the ondansetron group were also more satisfied
.
Although there was less vomiting in the ondansetron group, the oral fluid intake of the two groups within 4 hours after randomization was similar (median, 10 mL), and there was no difference in the referral rate and hospitalization rate between the two groups
.
Ondansetron was not associated with adverse effects
.
Comment: Family physicians and pediatricians often encounter young children who suffer from gastroenteritis and are at risk of dehydration due to persistent vomiting
.
A single dose of ondansetron in primary care clinics appears to be safe and reasonable, and this observation may have important implications
.
The amount of oral rehydration in both groups in the study was very small, which highlights the importance of emphasizing oral rehydration recommendations
.
Commented article Bonvanie IJ et al.
Oral ondansetron for paediatric gastroenteritis in primary care: A randomised controlled trial.
Br J Gen Pract 2021 Oct; 71:e728.
(https://doi.
org/10.
3399/BJGP.
2021.
0211) Related reading NEJM Journal Watch is published by NEJM Group.
Internationally renowned doctors are invited to comment on important papers in the medical field to help doctors understand and use the latest developments
.
"NEJM Frontiers in Medicine" is translated several times a week, published on the app and official website, and selected 2-3 articles are published on WeChat
.
Copyright information This article was translated, written or commissioned by the "NEJM Frontiers of Medicine" jointly created by the Jiahui Medical Research and Education Group (J-Med) and the "New England Journal of Medicine" (NEJM)
.
The Chinese translation of the full text and the included diagrams are exclusively authorized by the NEJM Group
.
If you need to reprint, please leave a message or contact nejmqianyan@nejmqianyan.
cn
.
Unauthorized translation is an infringement, and the copyright owner reserves the right to pursue legal liabilities
.
.
Acute gastroenteritis is usually self-limiting, and oral rehydration is the main treatment
.
However, persistent vomiting in the child indicates failure of oral rehydration
.
Emergency department studies have demonstrated the effects of oral ondansetron in restricting vomiting and improving oral rehydration (NEJM JW Gen Med May 15 2006 and N Engl J Med 2006; 354:1698), but its role in primary treatment has not been Clear
.
The trial included 194 children (age range, age range, 6 months to 6 years old), the investigator randomly assigned them to receive standard treatment (only the prescription of oral rehydration solution) or standard treatment combined with a single oral dose of ondansetron (0.
1 mg/kg)
.
The parents of the child will record the child’s symptoms/fluid intake in detail every day for the next 4 hours and the following 7 days
.
Significantly fewer children in the ondansetron group had vomiting in the next 4 hours (19.
5% vs.
42.
9%), and parents in the ondansetron group were also more satisfied
.
Although there was less vomiting in the ondansetron group, the oral fluid intake of the two groups within 4 hours after randomization was similar (median, 10 mL), and there was no difference in the referral rate and hospitalization rate between the two groups
.
Ondansetron was not associated with adverse effects
.
Comment: Family physicians and pediatricians often encounter young children who suffer from gastroenteritis and are at risk of dehydration due to persistent vomiting
.
A single dose of ondansetron in primary care clinics appears to be safe and reasonable, and this observation may have important implications
.
The amount of oral rehydration in both groups in the study was very small, which highlights the importance of emphasizing oral rehydration recommendations
.
Commented article Bonvanie IJ et al.
Oral ondansetron for paediatric gastroenteritis in primary care: A randomised controlled trial.
Br J Gen Pract 2021 Oct; 71:e728.
(https://doi.
org/10.
3399/BJGP.
2021.
0211) Related reading NEJM Journal Watch is published by NEJM Group.
Internationally renowned doctors are invited to comment on important papers in the medical field to help doctors understand and use the latest developments
.
"NEJM Frontiers in Medicine" is translated several times a week, published on the app and official website, and selected 2-3 articles are published on WeChat
.
Copyright information This article was translated, written or commissioned by the "NEJM Frontiers of Medicine" jointly created by the Jiahui Medical Research and Education Group (J-Med) and the "New England Journal of Medicine" (NEJM)
.
The Chinese translation of the full text and the included diagrams are exclusively authorized by the NEJM Group
.
If you need to reprint, please leave a message or contact nejmqianyan@nejmqianyan.
cn
.
Unauthorized translation is an infringement, and the copyright owner reserves the right to pursue legal liabilities
.